Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2015

Open Access 01-12-2015 | Research article

Anti-emetic mechanisms of zingiber officinale against cisplatin induced emesis in the pigeon; behavioral and neurochemical correlates

Authors: Ihsan Ullah, Fazal Subhan, Muhammad Ayaz, Rehmat Shah, Gowhar Ali, Ikram Ul Haq, Sami Ullah

Published in: BMC Complementary Medicine and Therapies | Issue 1/2015

Login to get access

Abstract

Background

Zingiber officinale (ZO, family Zingiberaceae) has been reported for its antiemetic activity against cancer chemotherapy induced emesis in animal models and in clinics. Current study was designed to investigate ZO for potential usefulness against cisplatin induced vomiting in pigeon and its effects on central and peripheral neurotransmitters involved in the act of vomiting.

Methods

Zingiber officinale acetone fraction (ZO-ActFr) was investigated for attenuation of emesis induced by cisplatin in healthy pigeons. Neurotransmitters DA, 5HT and their metabolites DOPAC, HVA and 5HIAA were analyzed using High Performance Liquid Chromatography system coupled with electrochemical detector in area postrema, brain stem and intestine. Antiemetic effect of ZO-ActFr was correlated with central and intestinal neurotransmitters levels in pigeon.

Results

Cisplatin (7 mg/kg i.v.) induced emesis without lethality upto the observation period. ZO-ActFr (25, 50 & 100 mg/kg) attenuated cisplatin induced emesis ~ 44.18%, 58.13% (P < 0.05) and 27.9%, respectively; the reference drug, metoclopramide (MCP; 30 mg/kg), produced ~ 48.83% reduction (P < 0.05). ZO-ActFr reduced (P < 0.05 - 0.001) 5-hydroxytryptamine (5HT) concentration in the area postrema, brain stem and intestine at 3rd hour of cisplatin administration, while at the 18th hour ZO treatments attenuated the dopamine upsurge (P < 0.001) caused by cisplatin in the area postrema and 5HT concentration (P < 0.01 - 0.001) in the brain stem and intestine. ZO treatments alone did not altered the basal neurotransmitters and their metabolites in the brain areas and intestine.

Conclusion

The behavioral study verify the antiemetic profile of ZO against cisplatin induced emesis in the pigeon, where central and peripheral neural evidences advocate the involvement of serotonergic mechanism at initial time point (3rd hr), while the later time point (18th hr) is associated with serotonergic and dopaminergic component in the mediation of its antiemetic effect.
Literature
1.
Hesketh P, Grunberg SMG RJ, Warr DG, Roila F, De Wit R, Chawla SP, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112–9.CrossRefPubMed
2.
Coronas R, Pitarch L, Mallol J. Blockade of reserpine emesis in pigeons by metoclopramide. Eur J Pharmacol. 1975;32(2):380–2.CrossRefPubMed
3.
Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 2012;88(3):497–9.CrossRef
4.
Higgins G, Kilpatrick G, Bunce K, Jones B, Tyers M. 5HT3 receptor antagonists injected into the area postrema inhibit cisplatin induced emesis in the ferret. Br J Pharmacol. 2012;97(1):247–55.CrossRef
5.
Perciedu Sert N, Rudd J, Apfel C, Andrews PLR. Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT3 receptor antagonists. Cancer Chemother Pharmacol. 2011;67(3):667–86.CrossRef
6.
Osinski MU, ME Miller LN, Seifert TS, TK Nakane M, Cox B, Brioni J, et al. Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005;81(1):211–9.CrossRefPubMed
7.
Darmani N, Crim J. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva). Pharmacol Biochem Behav. 2005;80(1):35–44.CrossRefPubMed
8.
Grelot LD J, Esteve EF A, Bianchi AL, Sheldrick RLG, Gardner CJ, Ward P. Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist. Br J Pharmacol. 2009;124(8):1643–50.CrossRef
9.
Tanihata S, Oda S, Kakuta S, Uchiyama T. Antiemetic effect of a tachykinin NK1 receptor antagonist GR205171 on cisplatin-induced early and delayed emesis in the pigeon. Eur J Pharmacol. 2003;461(2–3):197–206.CrossRefPubMed
10.
Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother. 2003;4(12):2297–303.CrossRefPubMed
11.
Minami M, Endo TH M, Hamaue N, Liu Y, Hiroshige T, Nemoto M, et al. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther. 2003;99(2):149–65.CrossRefPubMed
12.
Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs. 2000;60(3):533–46.CrossRefPubMed
13.
Wolff MC, Leander JD. Effects of a 5-HT1A receptor agonist on acute and delayed cyclophosphamide-induced vomiting. Eur J Pharmacol. 1997;340(2–3):217–20.CrossRefPubMed
14.
Cubeddu L, O'Connor D, Hoffmann I, Parmer R. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies. Br J Cancer. 1995;72(4):1033–8.CrossRefPubMedPubMedCentral
15.
Veyrat-Follet C, Farinotti R, Palmer JL. Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds. Drugs. 1997;53(2):206–34.CrossRefPubMed
16.
Endo T, Takahashi M, Minami M, Yoshioka M, Saito H, Parvez S. Effects of anticancer drugs on enzyme activities and serotonin release from ileal tissue in ferrets. Biogenic Amines. 1993;9(5–6):479–89.
17.
Yoshikawa T, Yoshida N, Hosoki K. Involvement of dopamine D3 receptors in the area postrema in R (+) 7-OH-DPAT induced emesis in the ferret. Eur J Pharmacol. 1996;301(1):143–9.CrossRefPubMed
18.
Darmani N, Zhao W, Ahmad B. The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew). J Neural Transm. 1999;106(11):1045–61.CrossRefPubMed
19.
Foss JF, Yuan CS, Roizen MF, Goldberg LI. Prevention of apomorphine-or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother Pharmacol. 1998;42(4):287–91.CrossRefPubMed
20.
Osinski MA, Seifert TR, Shaughnessy TK, Gintant GA, Cox BF. Emetic liability testing in ferrets. Current Protocols Pharmacol. 2003;5:31–5.
21.
Schofferman JA. A clinical comparison of syrup of ipecac and apomorphine use in adults. J Am College Emergency Physicians. 1976;5(1):22–5.CrossRef
22.
23.
Zia-Ul-Haq M, Shahid SA, Muhammed S, Qayum M, Khan I, Ahmad S. Antimalarial, antiemetic and antidiabetic potential of Grewia aslatica L. leaves. J Med Plant Res. 2012;6(16):3087–92.
24.
Darmani N. Delta (9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology. 2001;24(2):198–203.CrossRefPubMed
25.
Sharma S, Kochupillai V, Gupta S, Seth S, Gupta Y. Antiemetic efficacy of ginger (Zingiber officinale) against cisplatin-induced emesis in dogs. J Ethnopharmacol. 1997;57(2):93–6.CrossRefPubMed
26.
Ullah I, Subhan F, Rudd JA, Rauf K, Alam J, Shahid M, et al. Attenuation of cisplatin-induced emetogenesis by Standardized Bacopa monniera extracts in the Pigeon: behavioral and neurochemical correlations. Planta Medica. 2014;80(17):1569–79.CrossRefPubMed
27.
Qiu-hai Q, Wang Y, Wen-hui C, Zhi-hong Y, Zhan-tao L, Yao-xia W. Effect of gingerol on substance P and NK1 receptor expression in a vomiting model of mink. Chin Med J. 2010;123(4):478–84.
28.
Tyler VE, Brady LR, Robbers JE. Phrmacognosy. 9th ed. Philadelphia: Lea and Febiger; 1988. p. 150.
29.
Ernst E, Pittler M. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth. 2000;84(3):367–71.CrossRefPubMed
30.
Ullah I, Subhan F, Rauf K, Badshah A, Ali G. Role of gastrointestinal motility/gastric emptying in cisplatin-induced vomiting in pigeon. Afr J Pharma Pharmacol. 2012;6(35):2592–9.CrossRef
31.
32.
Preziosi P, Amanto MD, Carmine RD, Martire M, Pozzoli G, Navarra P. the effects of 5-HT3 receptor antagonists on cisplatin-induced emesis in the pigeon. Eur J Pharmacol. 1992;221:343–50.CrossRefPubMed
33.
Karten H, Hodos W. A stereotaxic atlas of the brain of the pigeon (Columba livia). Baltimore: Johns Hopkins Press Baltimore; 1967.
34.
Duvernoy H, Risold P. The circumventricular organs: an atlas of comparative anatomy and vascularization. Brain Res Rev. 2007;56(1):119–47.CrossRefPubMed
35.
Rauf K, Subhan F, Sewell RDE: A Bacoside Containing Bacopa monnieri Extract Reduces Both Morphine Hyperactivity Plus the Elevated Striatal Dopamine and Serotonin Turnover. Phytotherapy Research 758–763 2011.
36.
Rai S, Mukherjee K, Mal M, Wahile A, Saha BP, Mukherjee PK. Determination of 6-gingerol in ginger (Zingiber officinale) using high performance thin layer chromatography. J Sep Sci. 2006;29(15):2292–5.CrossRefPubMed
37.
Abdel-Aziz H, Windeck T, Ploch M, Verspohl EJ. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol. 2006;530(1–2):136–43.CrossRefPubMed
38.
Yamahara J, Rong HQ, Iwamoto M, Kobayashi G, Matsuda H, Fujimura H. Active components of ginger exhibiting anti-serotonergic action. Phytother Res. 1989;3(2):70–1.CrossRef
39.
Al-Zubaidy MHI, Mohammad FK. Metoclopramide-induced central nervous system depression in the chicken. BMC Vet Res. 2005;1(1):2–6.CrossRef
40.
41.
Johnston KD, Lu Z, Rudd JA. Looking beyond 5-HT3 receptors: a review of the wider role of serotonin in the pharmacology of nausea and vomiting. Eur J Pharmacol. 2014;722:13–25.CrossRefPubMed
42.
Saito R, Takano Y, Kamiya H. Roles of substance P and NK1 receptor in the brainstem in the development of emesis. J Pharmacol Sci. 2003;91(2):87–94.CrossRefPubMed
43.
Hesketh P, Van Belle SA M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003;39(8):1074–80.CrossRefPubMed
44.
Navari R: Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Newer Agents and New Uses for Older Agents. Drugs 2013.
45.
De Jonghe BC, Horn CC. Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). Am J Physiol Regul Integr Comp Physiol. 2009;296(4):R902–11.CrossRefPubMedPubMedCentral
46.
Darmani NA, Crim JL, Janoyan JJ, Abad J, Ramirez J. A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res. 2009;1248:40–58.CrossRefPubMed
Metadata
Title
Anti-emetic mechanisms of zingiber officinale against cisplatin induced emesis in the pigeon; behavioral and neurochemical correlates
Authors
Ihsan Ullah
Fazal Subhan
Muhammad Ayaz
Rehmat Shah
Gowhar Ali
Ikram Ul Haq
Sami Ullah
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2015
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-015-0556-0

Other articles of this Issue 1/2015

BMC Complementary Medicine and Therapies 1/2015 Go to the issue

Research article

Quantitative structure-activity relationship of molecules constituent of different essential oils with antimycobacterial activity against Mycobacterium tuberculosis and Mycobacterium bovis

Research article

Effects of Antrodia camphorata extracts on anti-oxidation, anti-mutagenesis and protection of DNA against hydroxyl radical damage

Research article

Evaluation of a spirituality informed e-mental health tool as an intervention for major depressive disorder in adolescents and young adults – a randomized controlled pilot trial

Research article

Molecular docking studies of (4Z, 12Z)-cyclopentadeca-4, 12-dienone from Grewia hirsuta with some targets related to type 2 diabetes

Research article

Effect of Uncaria tomentosa extract on purinergic enzyme activities in lymphocytes of rats submitted to experimental adjuvant arthritis model

Research article

Antifungal properties of a new terpernoid saponin and other compounds from the stem bark of Polyscias fulva Hiern (Araliaceae)